IncellvuS.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2024-01-23
Share capital
3 306 050,00 PLN
Activity description

Incellvu is a company that develops innovative devices for ultra-fast volumetric imaging of the cellular structure of the human retina in vivo. They aim to create an optical coherence tomography (OCT) system for non-invasive imaging of the eye's structure and function with microscopic resolution, supporting the diagnosis of eye diseases and gene therapies to prevent vision loss. Their technology, known as spatio-temporal optical coherence tomography (STOC-T), allows for high-resolution imaging and functional analysis of the retina.

Registered address
ul. Skierniewicka 10A, 01-230 Warszawa, Poland
Website
incellvu.plWebsite active
Social media
Electronic delivery address
AE:PL-26649-64477-HBFVG-23

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 6.99kMedianUSD 126.89kAverageUSD 4.67m
Net profit
This companyUSD -558.98kMedianUSD -19.64AverageUSD 371.62k
Operating costs
This companyUSD 564.59kMedianUSD 165.83kAverageUSD 4.01m
Assets
This companyUSD 1.69mMedianUSD 251.40kAverageUSD 7.40m

Bank accounts

Registered as a VAT taxpayer on 2020-08-01. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

Grant datePurposeGross amountGranting body
Nov 7, 2022
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$2,582Prezes Polskiej Agencji Rozwoju Przedsiębiorczości

Tenders

No recorded participation in tenders.

Authorized Representatives

Łukasz Waldemar Kornaszewski — President of the Management Board

Manner of representation

One member of the management board acting independently is authorized to make declarations of will and sign on behalf of the company.

Supervisory board

Adam Krzysztof Roślewski — Supervisory Board Member
Edward Aleksander Wylęgała — Supervisory Board Member
Dawid Mateusz Borycki — Supervisory Board Member
Jacek Witold Gregorowicz — Supervisory Board Member
Krzysztof Jassem — Supervisory Board Member

Beneficial owners

PersonRights
Michał Piotr Błach (54)
Shareholder of a joint-stock company, 32.39%

Competitors

NameRevenueWebsite
Digital Pathology Teamsp. z o.o.$64,552.91digitalpathologyteam.com
Luna Laboratorysp. z o.o.$61,894.23lunalab.pl
Biostat Research And Developmentsp. z o.o.$50,225.77biostat.com.pl
Stenocoatsp. z o.o.$36,665.21stenocoat.com
Medaisp. z o.o.$22,311.83medai.pl
Muotechsp. z o.o.$21,191.78muotech.io
InventroS.A.$12,176.61inventro.co
Oncotherics PolandS.A.$7,565.33oncotherics.com
Poltisssp. z o.o.$3,843.72poltiss.com

Change history

DateEvent
2025-07-10Share capital change (2,706,050.00 PLN → 3,306,050.00 PLN)
2025-02-25Address change (Ul. Skierniewicka 16/20, 01-230, Warszawa → Ul. Skierniewicka 10a, 01-230, Warszawa)
2025-02-25Share capital change (2,615,050.00 PLN → 2,706,050.00 PLN)
2025-02-24PKD change (Removed: 32.50.Z, 62.01.Z, 71.12.Z, 71.20.B, 72.19.Z; Added: 32.50.B, 62.10.B, 71.12.B, 71.20.C, 72.10.Z)
2024-05-29Share capital change (2,175,050.00 PLN → 2,615,050.00 PLN)

FAQ

Last updated: 2026-07-02